If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
129
results.
Updated on
23/12/2025 [06:57:00]
Absstract of: CN120858927A
The invention relates to a construction and evaluation method of an animal model of Alzheimer's disease spleen and kidney deficiency and phlegm and blood stasis syndrome based on combination of diseases and syndromes, and belongs to the technical field of construction of animal models combined with diseases and syndromes. A double transgenic APP/PS1 mouse is taken as an AD model animal, a standard animal model of AD spleen and kidney deficiency and phlegm and blood stasis syndrome is constructed by adopting high-glucose and high-fat diet feeding in combination with ice-water bath and tail-clamping stimulation intervention, and the model is subjected to'disease-syndrome-prescription-effect 'comprehensive judgment from four dimensions of a modeling method, macroscopic characterization, microscopic characterization and prescription-based test. The method aims to construct a reproducible and standardized animal model with the AD spleen and kidney deficiency and the phlegm and blood stasis syndrome, and a scientific basis is provided for construction of a disease-syndrome-prescription-effect diagnosis and treatment normal form of the AD spleen and kidney deficiency and the phlegm and blood stasis syndrome. Meanwhile, the mold manufactured through the method has the advantages of being high in controllability, small in physical and chemical property stimulation, capable of being copied and verified and the like.
Absstract of: JP2025029000A
To provide a method for detecting a neurodegenerative disease of a subject, and a method for treating the subject.SOLUTION: A method includes a step of detecting a level of exosome-associated coagulation biomarkers in a specimen collected from a subject. In the method, an increased level of exosome-associated coagulation biomarkers compared to a reference level indicates that the subject is suffering from a neurodegenerative disease.SELECTED DRAWING: None
Absstract of: AU2024284125A1
Disclosed herein are methods for detecting the presence of at least one misfolded form of human Superoxide Dismutase 1 (SOD1) in a biological sample obtained from a human subject. In some aspects, the subject is suspected of having, or has, one or more neurodegenerative diseases, such as, for example, Amyotrophic Lateral Sclerosis, Parkinson's disease, or Alzheimer's disease.
Absstract of: US2025334583A1
Provided is a method for analyzing a neurogranin-related peptide capable of suppressing variations in analysis results, and a method for preparing a biological sample containing a neurogranin-related peptide used therein. The method includes mixing a biological sample containing a neurogranin-related peptide with an organic solvent having a relative polarity of 0.200 or more and 0.700 or less to prepare a sample solution having a final concentration of the organic solvent of 5.0 (v/v) % or more.
Absstract of: US2025334585A1
Antigen-binding molecules (ABMs) that bind to Porphyromonas gingivalis are described. The ABMs may be human or humanized ABMs. The ABMs find use in treating infections involving P. gingivalis, such as periodontal disease. Also provided are methods of treating or preventing a disorder or disease by administering the ABM.
Absstract of: US2025334594A1
Provided herein are methods and kits for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia. Also provided are methods of predicting or measuring a response to a treatment by measuring biomarker levels in a sample, and methods of modulating biomarker levels.
Absstract of: AU2024235526A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Absstract of: US2024159777A1
This invention provides methods for determining whether a subject has a condition correlative with a matrix effect comprising (a) admixing (i) a suitably diluted sample of a suitable fluid from the subject and (ii) a suitable amount of a labeled molecule, wherein the labeled molecule is subject to a matrix effect with respect to the suitable fluid in a subject afflicted with the condition, and (b) after a suitable duration under suitable conditions, determining the amount of matrix-unaffected labeled molecule present in the resulting admixture, wherein the subject is afflicted with the condition if the amount of matrix-unaffected labeled molecule determined in step (b) correlates with a positive control for the condition, and wherein the subject is not afflicted with the condition if that amount correlates with a negative control for the condition. This invention also provides related methods, kits, and compositions. The present methods and kits are particularly useful for predicting the onset of neurodegenerative disorders such Alzheimer's disease and Parkinson's disease.
Absstract of: US2025361504A1
The present disclosure relates, in general, to methods of preparing a spatial proteome and/or transcriptome sequencing library. The spatial proteome and/or transcriptome sequencing library from a biological sample is useful, in some aspects, to determine a genetic profile and help diagnose a subject who has or is at risk of having a disorder, and improve treatment of the subject.
Nº publicación: JP2025535729A 28/10/2025
Applicant:
ザ・ホンコン・ユニバーシティー・オブ・サイエンス・アンド・テクノロジー
Absstract of: CN120129834A
A protein marker Nell-1 is provided that is present in a blood sample of a human in an amount associated with neurodegenerative diseases such as Alzheimer's disease (AD), mild cognitive impairment (MCI), and Parkinson's disease (PD). Also provided are corresponding diagnostic and therapeutic methods for these neurodegenerative diseases, as well as kits for diagnosing or treating neurodegenerative diseases.
BOPI
Electronic site
